Company intelligence / Profile preview

Genitope Corporation

Redwood City / Fremont*, California, United States

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Genitope developed MyVax®, a personalized immunotherapy for previously untreated follicular B-cell non-Hodgkin's lymphoma. The pivotal Phase 3 trial failed to meet its primary endpoint of improved progression-free survival versus control, though a subset analysis showed benefit in patients mounting an immune response. Following FDA feedback that further Phase 3 trials would be required, the company suspended development of MyVax® and ceased major operations[4].

Therapeutic areas: Oncology
Modalities: Personalized active immunotherapy (patient-specific vaccines)Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

MyVax

Partnerships

No major pharmaceutical partnerships reported before closure.

Beyond the preview

Go deeper on Genitope Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genitope Corporation.